» Articles » PMID: 20530792

Identifying Drugs That Cause Acute Thrombocytopenia: an Analysis Using 3 Distinct Methods

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 Jun 10
PMID 20530792
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Drug-induced immune thrombocytopenia (DITP) is often suspected in patients with acute thrombocytopenia unexplained by other causes, but documenting that a drug is the cause of thrombocytopenia can be challenging. To provide a resource for diagnosis of DITP and for drug safety surveillance, we analyzed 3 distinct methods for identifying drugs that may cause thrombocytopenia. (1) Published case reports of DITP have described 253 drugs suspected of causing thrombocytopenia; using defined clinical criteria, 87 (34%) were identified with evidence that the drug caused thrombocytopenia. (2) Serum samples from patients with suspected DITP were tested for 202 drugs; drug-dependent, platelet-reactive antibodies were identified for 67 drugs (33%). (3) The Food and Drug Administration's Adverse Event Reporting System database was searched for drugs associated with thrombocytopenia by use of data mining algorithms; 1444 drugs had at least 1 report associated with thrombocytopenia, and 573 (40%) drugs demonstrated a statistically distinctive reporting association with thrombocytopenia. Among 1468 drugs suspected of causing thrombocytopenia, 102 were evaluated by all 3 methods, and 23 of these 102 drugs had evidence for an association with thrombocytopenia by all 3 methods. Multiple methods, each with a distinct perspective, can contribute to the identification of drugs that can cause thrombocytopenia.

Citing Articles

A Case Report of Ticagrelor-Induced Thrombocytopenia.

Alsalman M Int Med Case Rep J. 2023; 16:401-405.

PMID: 37426310 PMC: 10329443. DOI: 10.2147/IMCRJ.S411209.


A Case of COVID-19-Induced Immune Thrombocytopenia (ITP) in an Adult Female: An Under-Recognized Emerging Phenomenon.

Ghukasyan H, Petrechko O, Choi H Cureus. 2023; 15(4):e38173.

PMID: 37122979 PMC: 10132859. DOI: 10.7759/cureus.38173.


Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.

He X, Huang W, Wan X, Li X, Chang Q, Ding L J Int Med Res. 2023; 51(3):3000605231162434.

PMID: 36967671 PMC: 10052494. DOI: 10.1177/03000605231162434.


Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.

Kuter D Haematologica. 2022; 107(6):1243-1263.

PMID: 35642485 PMC: 9152964. DOI: 10.3324/haematol.2021.279512.


Detection of Drug-Induced Thrombocytopenia Signals in Children Using Routine Electronic Medical Records.

Nie X, Jia L, Peng X, Zhao H, Yu Y, Chen Z Front Pharmacol. 2021; 12:756207.

PMID: 34867372 PMC: 8633439. DOI: 10.3389/fphar.2021.756207.


References
1.
Warkentin T . Think of HIT. Hematology Am Soc Hematol Educ Program. 2006; :408-14. DOI: 10.1182/asheducation-2006.1.408. View

2.
Van den Bemt P, Meyboom R, Egberts A . Drug-induced immune thrombocytopenia. Drug Saf. 2004; 27(15):1243-52. DOI: 10.2165/00002018-200427150-00007. View

3.
Aster R, Bougie D . Drug-induced immune thrombocytopenia. N Engl J Med. 2007; 357(6):580-7. DOI: 10.1056/NEJMra066469. View

4.
Bougie D, Wilker P, Wuitschick E, Curtis B, Malik M, Levine S . Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002; 100(6):2071-6. View

5.
Swisher K, Li X, Vesely S, George J . Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf. 2009; 32(1):85-6. DOI: 10.2165/00002018-200932010-00008. View